COVID-19 emerged in Wuhan, China in late December 2019, and WHO declared it a
pandemic on March 11, 2020. The disease has a wide spectrum ranging from asymptomatic …

Rising incidence of thromboembolism secondary to COVID-19 has become a global
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …

Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including …

Many aspects of care such as management of hypercoagulable state in COVID-19 patients,
especially those admitted to intensive care units is challenging in the rapidly evolving …

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) which has posed a significant threat to …

Background: COVID-19 patients are at high thrombotic risk. The safety and efficacy of
different anticoagulation regimens in COVID-19 patients remain unclear. Methods: We …

As patients with COVID-19 pneumonia admitted to intensive care unit (ICU) have high rates
of thrombosis, high doses of thromboprophylaxis have been proposed. The associated …

As observed in other infections with a systemic inflammatory response, severe COVID-19 is
associated with hypercoagulability and a prothrombotic state. Currently, there is growing …

Introduction COVID-19 induces venous, arterial and microvascular thrombosis, involving
several pathophysiological processes. In patients with severe COVID-19 without …

As of September 19th, 2020, more than 30 million cases of novel coronavirus disease 2019
(COVID-19), the clinical syndrome caused by severe acute respiratory syndrome …